drugset / Trial / NCT02610348
Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age
Non-randomizedParallel-groupOpen-labelOther
Summary
Primary Objective: To describe the persistence of Hep B antibodies (Ab) at 12 to 18 months of age following a three-dose infant primary series vaccination of either Hexaxim®/Hexyon®/Hexacima® or Infanrix® hexa at 2, 4 and 6 months of age following Hep B vaccination at birth.
Timeline
- Start
- 2015-11
- Primary completion
- 2015-12
- Completion
- 2016-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DTaP-HB-IPV | Vaccine | — | — |
| Subject | DTaP-IPV-HB-PRP~T | Vaccine | — | — |